Sign in
CompletedNo phase

MIND After Surgery

Key facts

Who runs it
McMaster University
Where
Canada2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
88 people enrolled
Started
14 Sept 2021
Ended
5 Jul 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Liquid Melatonin
  • Placebo
Record updated
12 September 2025

Who can take part

Age
65 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Age >65 years
  • having a major non-cardiac surgery (which involve major vascular, thoracic, orthopedic, gynecological, otolaryngeal, general and gastrointestinal surgeries) with an expected hospital stay of 2 days or more, and
  • ability to provide informed consent

Who cannot take part

  • unable to take oral medications
  • previous study participation
  • previous liver transplant or liver cirrhosis of Child-Pugh classes B and C
  • active delirium or dementia
  • allergy to melatonin
  • hepatic impairment defined as alanine aminotransferase greater than 500 IU/L
  • ongoing melatonin treatment
  • planned postoperative ventilation
  • not willing to participate
  • language barrier

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Delirium is the most common neurological adverse outcome in elderly surgical patients. It is associated with an increased mortality and morbidity, including need for prolonged hospital stay and institutional care. Despite this, there are no effective preventive strategies. Melatonin is a hormone released from the pineal gland. It is used to improve sleep quality and to treat jet lag. Small studies have suggested that it can decrease the chances of delirium. Since the existing literature is small and uncertain, it is important to test its benefit in a large sample to help guide clinicians. This proposed trial is aimed at testing assessing the feasibility of a large, multi-center, randomized control trial to decrease the incidence of postoperative delirium.

The 2 groups in the trial

  • MelatoninExisting treatment, for comparison

    3 mg of liquid melatonin by oral route for 8 days. The 1st dose will be given 1-2 hours prior to the surgery, followed by bed time doses (between 7-9 pm) given on postoperative day (POD) 1 until discharge or for the first 7 days.

    Treatment: Liquid Melatonin

  • Placebo GroupPlacebo, for comparison

    Similar looking/tasting 3 mg (5 ml) placebo syrup administered preoperatively by oral route and for the next 7 days or until discharge. The 1st dose will be given 1-2 hours prior to the surgery, followed by bed time doses (between 7-9 pm) given on postoperative day (POD) 1 until discharge or for the first 7 days.

    Treatment: Placebo

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Melatonin for Preventing Postoperative Delirium in Elderly Patients; a Multi-centre Randomized Placebo Controlled Pilot Study
Record updated
12 September 2025